Inflammatory disease and related syndromes are growing in prevalence among Western societies. These diseases affect close to 60 million people in the US and place a significant burden on the healthcare system.1 Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression.
Patients require healthcare attention but are initially hidden from a clinician's view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders.
In this webinar, the featured speaker will discuss:
The application presented is for Research Use Only. Not for use in diagnostic procedures.
1Wylezinski, L.S., Gray, J.D., Polk, P.B. Harmata, A.J., and Spurlock, C.F. 2019. Illuminating an invisible epidemic: a systematic review of the clinical and economic benefits of early diagnosis and treatment in inflammatory disease and related syndromes. J Clin Med 8: 493.
Dr. Chase Spurlock is Founder and CEO of IQuity, a Nashville-based data analytics company that works with stakeholders to lower the cost of healthcare and improve outcomes by finding and fixing addressable autoimmune disease risk. Dr. Spurlock is a Phi Beta Kappa graduate of The University of the South and received his PhD in immunology from Vanderbilt University, where he also serves on the faculty. His work in genomics and data science has been featured in peer-reviewed journals and widely published in trade journals and healthcare media outlets. He is also an industry innovator listed on the Nashville Business Journal '40 under 40' list and Nashville Medical News InCharge.